Filtered By:
Condition: Thrombosis
Procedure: Transplants

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 252 results found since Jan 2013.

First Implantation in Man of a New Magnetically Levitated Left Ventricular Assist Device (HeartMate III)
Outcomes of heart failure patients supported by a continuous flow left ventricular assist device (LVAD) have steadily improved over the past decade due in large part to better patient selection and management 1,2. Nevertheless, adverse events such as bleeding, infection, stroke and thrombus persist and limit the overall effectiveness of this therapy. Bleeding is the most common serious adverse event that results from the extensive surgery required for implantation and blood component damage due to shear forces in the small blood flow paths of current design axial-flow and centrifugal-flow pumps.
Source: The Journal of Heart and Lung Transplantation - March 7, 2015 Category: Transplant Surgery Authors: Jan D. Schmitto, Jasmin S. Hanke, Sebastian V. Rojas, Murat Avsar, Axel Haverich Source Type: research

Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation
Conclusions In our population of HD patients with AF, the mortality is very high. OAT is not associated with increased mortality, while antiplatelet drugs are. OAT seems, on the contrary, associated with a better survival; however, it does not decrease the incidence of ischaemic stroke, whereas it increases the incidence of bleeding. Bleeding risk is lower in subjects in whom the INR is kept within the therapeutic range.
Source: Nephrology Dialysis Transplantation - February 23, 2015 Category: Urology & Nephrology Authors: Genovesi, S., Rossi, E., Gallieni, M., Stella, A., Badiali, F., Conte, F., Pasquali, S., Bertoli, S., Ondei, P., Bonforte, G., Pozzi, C., Rebora, P., Valsecchi, M. G., Santoro, A. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Left Ventricular Assist Device Thrombosis In The Setting of Left Ventricular Recovery
Left ventricular assist device (LVAD) thrombosis has become increasingly recognized as a complication of mechanical circulatory support.1,2 Morbidity, including increased rate of stroke, and a marked increase in mortality are seen with LVAD thrombosis.1
Source: The Journal of Heart and Lung Transplantation - December 23, 2014 Category: Transplant Surgery Authors: Thomas E. Hurst, Nader Moazami, Randall C. Starling Source Type: research

Intraluminal Cell Transplantation Prevents Growth and Rupture in a Model of Rupture-Prone Saccular Aneurysms Basic Sciences
Conclusions— Lack of smooth muscle cells in the aneurysm wall promotes wall degradation, aneurysm growth and rupture, even if the aneurysm is occluded by luminal thrombus. Transplantation of smooth muscle cells into the luminal thrombus can reduce this degenerative remodeling.
Source: Stroke - November 24, 2014 Category: Neurology Authors: Marbacher, S., Frosen, J., Marjamaa, J., Anisimov, A., Honkanen, P., von Gunten, M., Abo-Ramadan, U., Hernesniemi, J., Niemela, M. Tags: Animal models of human disease, Arterial thrombosis, Other Vascular biology Basic Sciences Source Type: research

High early cardiovascular mortality after liver transplantation
In conclusion, we provide the first multicenter prognostic model for the prediction of early post‐LT CVD death, the most common cause of early post‐LT mortality in the current transplant era. However, evaluations of additional CVD‐related variables not collected by the OPTN are needed in order to improve the model's accuracy and potential clinical utility. Liver Transpl, 2014. © 2014 AASLD.
Source: Liver Transplantation - October 24, 2014 Category: Transplant Surgery Authors: Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

Postoperative Stroke Following Administration of Intraoperative Recombinant Tissue Plasminogen Activator for the Treatment of Intracardiac Thrombus During Liver Transplantation: A Report of Two Cases
MASSIVE INTRACARDIAC AND PULMONARY thromboembolism have an extremely high mortality during liver transplantation.1,2 The authors describe 2 cases in which intraoperative use of tissue plasminogen activator was able to reduce the thrombus size and improve hemodynamics during liver transplantation. Although both patients survived the surgery, they suffered neurologic sequelae postoperatively. The authors discuss the current understanding of the pathophysiology, diagnosis, and management of intracardiac thromboembolism during liver transplantation.
Source: Journal of Cardiothoracic and Vascular Anesthesia - October 22, 2014 Category: Anesthesiology Authors: Stephen Aniskevich, Beth L. Ladlie, Sher-Lu Pai, Dana K. Perry, Juan M. Canabal, C. Burcin Taner Tags: Case Report Source Type: research

Acute bacterial infection negatively impacts cancer specific survival of colorectal cancer patients.
CONCLUSION: Infection and high neutrophil counts are associated with a poorer cancer-specific survival in colorectal cancer patients. PMID: 25320529 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - October 14, 2014 Category: Gastroenterology Authors: Attiê R, Chinen LT, Yoshioka EM, Silva MC, de Lima VC Tags: World J Gastroenterol Source Type: research

019 * is antiplatelet therapy required in heartmate ii patients? preliminary results from the european trace study
Conclusion: This preliminary analysis of the observational TRACE-EU study suggests that managing HMII patients with a vitamin K antagonist without aspirin may help to reduce the incidence of major bleeding without increasing the risk of thrombo-embolic events including ischaemic stroke and device thrombosis. Further prospective studies are needed.
Source: Interactive CardioVascular and Thoracic Surgery - September 23, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Schmitto, J. D., Litzler, P. Y., Berchtold-Herz, M., Flecher, E., Zimpfer, D., Damme, L., Sundareswaran, K., Netuka, I. Tags: Left ventricular assist devices: Softening the blow Source Type: research

Early power elevations and adverse events with the HeartMate II left ventricular assist device: An unsettled issue
In a recent issue of this journal, Salerno et al1 evaluated the prevalence and potential impact of early power elevation (PEL) events (power ≥10 W in the first 14 days after implant) on future adverse outcomes, including mortality, hemorrhagic and ischemic stroke, hemolysis and pump thrombosis, among 138 patients requiring implantation of a HeartMate II left ventricular assist device (LVAD). Patients with a PEL (20%) had similar survival, complications rates and late power elevations compared with patients without a PEL.
Source: The Journal of Heart and Lung Transplantation - September 10, 2014 Category: Transplant Surgery Authors: Omar Wever-Pinzon, Ulrich P. Jorde Tags: Case Anecdotes, Comments and Opinions Source Type: research

High early cardiovascular mortality following liver transplantation
Abstract Cardiovascular disease (CVD) contributes to excess long‐term mortality after liver transplantation (LT), however little is known about early post‐operative CVD mortality in the current era. In addition, there is no model to predict early post‐operative CVD mortality across centers. We analyzed adult recipients of primary LT in the Organ Procurement and Transplantation Network (OPTN) database between February 2002 and December 2012 to assess prevalence and predictors of early (30‐day) CVD mortality, defined as death from arrhythmia, heart failure, myocardial infarction, cardiac arrest, thromboembolism, and/...
Source: Liver Transplantation - July 5, 2014 Category: Transplant Surgery Authors: Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation
In conclusion, SAEs after donation are rare but more often occurred in BM donors and women. In addition, there was no evidence of increased risk for cancer, autoimmune illness, and stroke in donors receiving granulocyte colony-stimulating factor during this period of observation.
Source: Blood - June 5, 2014 Category: Hematology Authors: Pulsipher, M. A., Chitphakdithai, P., Logan, B. R., Navarro, W. H., Levine, J. E., Miller, J. P., Shaw, B. E., O'Donnell, P. V., Majhail, N. S., Confer, D. L. Tags: Transfusion Medicine, Transplantation Source Type: research

Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: Risk factors, diagnosis and treatment
Cerebral infarction and hemorrhage are among the principal sources of morbidity and mortality associated with mechanical circulatory support. There has been particular concern with the recently reported increased rate of device thrombosis in continuous-flow left ventricular assist devices. The neurologic management of stroke among these patients has limited data to inform current clinical practices. In this investigation we review the available literature on stroke in patients with continuous-flow left ventricular assist devices, with a focus on treatment algorithms in the acute setting and for secondary stroke prevention.
Source: The Journal of Heart and Lung Transplantation - May 31, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey, Ryan T. Demmer, Hiroo Takayama, Paolo C. Colombo, Ronald M. Lazar Source Type: research

Coagulation management with factor concentrates in liver transplantation: a single-center experience.
CONCLUSION: In LT, ROTEM-guided treatment with fibrinogen concentrate and/or PCC did not appear to increase the occurrence of thrombosis and ischemic events compared to patients who did not receive these concentrates. PMID: 24827116 [PubMed - as supplied by publisher]
Source: Transfusion - May 14, 2014 Category: Hematology Authors: Kirchner C, Dirkmann D, Treckmann JW, Paul A, Hartmann M, Saner FH, Görlinger K Tags: Transfusion Source Type: research

RNase A in (Xeno)Transplantation
ConclusionsRNase A significantly improved graft survival. On the basis of these sweeping results, however, we suppose that RNase A could be an important adjuvant drug not only in allotransplantation but even in xenotransplantation. References[1] Fischer S, Gerriets T, Wessels C, et al. Extracellular RNA mediates endothelial‐cell permeability via vascular endothelial growth factor. Blood 2007; 110(7): 2457–2465.[2] Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104(15): 6388–6393.[3] Fischer S, Grantzow T,...
Source: Xenotransplantation - April 19, 2014 Category: Transplant Surgery Authors: Eike Kleinert, Bruno Reichart, Tanja Mayr, Jan‐Michael Abicht, Paolo Brenner, Christian Hagl, Martin Langenmayer, Ruediger Wanke, Elisabeth Deindl, Sonja Guethoff Tags: Program and Abstracts Source Type: research

Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: A Japanese multicenter study using J-MACS
Conclusions: The EVAHEART device provides safe, reliable and long-term circulatory support with improved survival in commercial settings of BTT in Japan, where the transplant waiting period is much longer. Incidences of GI bleeding, hemolysis, right ventricular failure, device thrombosis and mechanical failure were extremely rare in patients on EVAHEART devices.
Source: The Journal of Heart and Lung Transplantation - March 6, 2014 Category: Transplant Surgery Authors: Satoshi Saito, Kenji Yamazaki, Tomohiro Nishinaka, Yuki Ichihara, Minoru Ono, Syunei Kyo, Takashi Nishimura, Takeshi Nakatani, Koichi Toda, Yoshiki Sawa, Ryuji Tominaga, Tadahisa Tanoue, Yoshikatsu Saiki, Yoshiro Matsui, Takahiro Takemura, Hiroshi Niinami Tags: Featured Articles Source Type: research